JP2021522779A5 - - Google Patents

Info

Publication number
JP2021522779A5
JP2021522779A5 JP2020556748A JP2020556748A JP2021522779A5 JP 2021522779 A5 JP2021522779 A5 JP 2021522779A5 JP 2020556748 A JP2020556748 A JP 2020556748A JP 2020556748 A JP2020556748 A JP 2020556748A JP 2021522779 A5 JP2021522779 A5 JP 2021522779A5
Authority
JP
Japan
Prior art keywords
peptide
binder
cancer
pharmaceutically acceptable
cell
Prior art date
Application number
JP2020556748A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019219312A5 (https=
JP7578491B2 (ja
JP2021522779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/059522 external-priority patent/WO2019219312A1/en
Publication of JP2021522779A publication Critical patent/JP2021522779A/ja
Publication of JPWO2019219312A5 publication Critical patent/JPWO2019219312A5/ja
Publication of JP2021522779A5 publication Critical patent/JP2021522779A5/ja
Priority to JP2024184854A priority Critical patent/JP2025016534A/ja
Application granted granted Critical
Publication of JP7578491B2 publication Critical patent/JP7578491B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020556748A 2018-05-16 2019-04-12 がんに対する免疫療法で使用するためのペプチド Active JP7578491B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024184854A JP2025016534A (ja) 2018-05-16 2024-10-21 がんに対する免疫療法で使用するためのペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862672411P 2018-05-16 2018-05-16
DE102018111819.8 2018-05-16
DE102018111819 2018-05-16
US62/672,411 2018-05-16
PCT/EP2019/059522 WO2019219312A1 (en) 2018-05-16 2019-04-12 Peptides for use in immunotherapy against cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024184854A Division JP2025016534A (ja) 2018-05-16 2024-10-21 がんに対する免疫療法で使用するためのペプチド

Publications (4)

Publication Number Publication Date
JP2021522779A JP2021522779A (ja) 2021-09-02
JPWO2019219312A5 JPWO2019219312A5 (https=) 2022-04-20
JP2021522779A5 true JP2021522779A5 (https=) 2022-04-20
JP7578491B2 JP7578491B2 (ja) 2024-11-06

Family

ID=66182582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020556748A Active JP7578491B2 (ja) 2018-05-16 2019-04-12 がんに対する免疫療法で使用するためのペプチド
JP2024184854A Pending JP2025016534A (ja) 2018-05-16 2024-10-21 がんに対する免疫療法で使用するためのペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024184854A Pending JP2025016534A (ja) 2018-05-16 2024-10-21 がんに対する免疫療法で使用するためのペプチド

Country Status (18)

Country Link
US (5) US11214604B2 (https=)
EP (1) EP3793592A1 (https=)
JP (2) JP7578491B2 (https=)
KR (1) KR20210010459A (https=)
CN (2) CN112135629A (https=)
AU (1) AU2019270985A1 (https=)
BR (1) BR112020021096A2 (https=)
CA (1) CA3097591A1 (https=)
CL (1) CL2020002935A1 (https=)
CO (1) CO2020013652A2 (https=)
CR (1) CR20200551A (https=)
MA (1) MA52614A (https=)
MX (1) MX2020012255A (https=)
PE (1) PE20210126A1 (https=)
PH (1) PH12020551958A1 (https=)
SG (2) SG10202110291WA (https=)
TW (1) TW202016131A (https=)
WO (1) WO2019219312A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN115785254A (zh) * 2019-12-13 2023-03-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
CN116334031A (zh) * 2022-07-21 2023-06-27 中国人民解放军陆军军医大学 三个多肽及其在制备ⅰ型糖尿病免疫防治疫苗或药物中的应用
CN115109117B (zh) * 2022-08-12 2024-08-16 齐鲁工业大学 一种多管藻藻红蛋白血管紧张素转化酶抑制肽及其制备方法与应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IL59007A (en) 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6635742B1 (en) * 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2322228B1 (en) 2000-06-05 2018-01-10 Altor BioScience Corporation T cell receptor fusion proteins and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
EP2520935A3 (en) * 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
EP2300040A4 (en) * 2008-05-01 2012-06-27 Beth Israel Hospital METHOD AND COMPOSITIONS FOR IMMUNOTHERAPY IN PROSTATE CANCER
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US12540318B2 (en) 2012-11-08 2026-02-03 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(二)
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
EA201892159A1 (ru) 2016-04-06 2019-03-29 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака
US11261223B2 (en) 2016-05-11 2022-03-01 The University Of Chicago Methods of treating cancers with CT45 targeted therapies
MA47367B1 (fr) * 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
US10800823B2 (en) * 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US20210061914A1 (en) 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine

Similar Documents

Publication Publication Date Title
JP2024099580A5 (https=)
JP2021535900A5 (https=)
JP2024041841A5 (https=)
Yamamoto et al. Developing neoantigen-targeted T cell–based treatments for solid tumors
JP2020516681A5 (https=)
JP2019511214A5 (https=)
JP2020191862A5 (https=)
JP2020198875A5 (https=)
JP2021514178A5 (https=)
JP2021522779A5 (https=)
JP2021168652A5 (https=)
JP2021528046A5 (https=)
JP2022502015A5 (https=)
JP2019502360A5 (https=)
JP2021101700A5 (https=)
JP2018510628A5 (https=)
JP2019510465A5 (https=)
JP2019506838A5 (https=)
JP2018529320A5 (https=)
HK1254962A1 (zh) 具有改进特异性的修饰的t淋巴细胞
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
JP2021521776A (ja) Mage−b2特異性を有するt細胞受容体およびその使用
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2019516663A5 (https=)
JP2018520653A5 (https=)